(Q37552101)

21 August 2017

High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib (English)

1 reference

21 August 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Francesca Gay

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Paolo Corradini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Alessandra Romano

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Marco Ladetto

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

12

Antonio Palumbo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Manuela Gambella

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Alberto Rocci

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Paola Omedè

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Claudia Crippa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Davide Rossi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Mario Boccadoro

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

1 February 2014

1 reference

21 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

e14-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.

4 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912976

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912976

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912976

International uniform response criteria for multiple myeloma.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912976

Plasma cell differentiation requires the transcription factor XBP-1

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912976

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912976

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912976

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912976

Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912976

Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma

1 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24497562

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2013.090142

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

PubMed publication ID

24497562

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24497562%20AND%20SRC:MED&resulttype=core&format=json